Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOVe-IN: Molnupiravir in Hospitalized COVID-19
NCT04575584Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Oct 2020
- Primary completion
- Aug 2021
- Modality
- RNA-Targeting Small Molecules, Metabolically Activated Prodrugs
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial of molnupiravir in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Merck & Co. Primary endpoints: Time-to-sustained Recovery at Day 29, Number of Participants With an Adverse Event at Day 19 and 1 more. Started Oct 2020; status: terminated.
02
Drugs
molnupiravir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04575584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04575584.